EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Spatial discovery of pyrotinib overcoming HER2-positive breast cancer resistance by breaking fibroblast-induced immune barriers

Chenghui Yang, Yiying Xu, Zhongmin Lin, Anqi Zhang, Lili Li, Zhiqiang Ye, Qiongying Zhang, Hanwen Hu, Guohong Ren, Pu Cheng, Zhen Wang, Ouchen Wang

Drug Resistance Updates · 2025

DOI: 10.1016/j.drup.2025.101261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2025. Verfasst von Chenghui Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, PR China; Zhejiang Key Laboratory of Intellige…. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Resistance, Neoplasm, Acrylamides, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhejiang Province Natural Science Foundation, Medical Science and Technology Project of Zhejiang Province, Discipline Cluster of Oncology, Wenzhou Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDrug Resistance, NeoplasmAcrylamidesAntineoplastic Combined Chemotherapy ProtocolsAminoquinolinesHumansFemaleErb-b2 Receptor Tyrosine KinasesTumor MicroenvironmentTrastuzumabCoculture TechniquesFibroblastsAntibodies, Monoclonal, HumanizedDocetaxelNeoadjuvant TherapyCell Line, TumorB7-H1 AntigenT-Lymphocytes, Cytotoxic

Stichwörter der Autor:innen

Breast cancerImaging mass cytometryNeoadjuvant therapyTreatment resistanceTyrosine kinase inhibitors

Substanzen

Erb-b2 Receptor Tyrosine KinasesAcrylamidesAminoquinolinesTrastuzumabAntibodies, Monoclonal, HumanizedDocetaxelB7-H1 AntigenERBB2 protein, humanpyrotinibpertuzumab

Autor:innen und Institutionen

  • Department of Breast Surgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, PR China; Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, First Affiliated Hospit…
  • The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou 324000, PR China.
  • Department of Pathology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, PR China.
  • Department of Anesthesiology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, PR China.
  • Department of Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, PR China; Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Second Affiliated…
  • Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, PR China.

Förderung

  • Zhejiang Province Natural Science Foundation
  • Medical Science and Technology Project of Zhejiang Province
  • Discipline Cluster of Oncology, Wenzhou Medical University
  • National Natural Science Foundation of China
  • Wenzhou Medical University

Zitieren

APA

Yang, C., Xu, Y., Lin, Z., Zhang, A., Li, L., Ye, Z., Zhang, Q., Hu, H., Ren, G., Cheng, P., Wang, Z., & Wang, O. (2025). Spatial discovery of pyrotinib overcoming HER2-positive breast cancer resistance by breaking fibroblast-induced immune barriers. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101261

Vancouver

Yang C, Xu Y, Lin Z, Zhang A, Li L, Ye Z, et al. Spatial discovery of pyrotinib overcoming HER2-positive breast cancer resistance by breaking fibroblast-induced immune barriers. Drug Resistance Updates. 2025. doi:10.1016/j.drup.2025.101261

BibTeX
@article{Yang2025,
  author = {Yang, Chenghui and Xu, Yiying and Lin, Zhongmin and Zhang, Anqi and Li, Lili and Ye, Zhiqiang and Zhang, Qiongying and Hu, Hanwen and Ren, Guohong and Cheng, Pu and Wang, Zhen and Wang, Ouchen},
  title = {Spatial discovery of pyrotinib overcoming HER2-positive breast cancer resistance by breaking fibroblast-induced immune barriers},
  journal = {Drug Resistance Updates},
  year = {2025},
  doi = {10.1016/j.drup.2025.101261}
}
Kostenlos starten →